Targeted EGFR Gene Mutation

• - Among the major causes of NSCLC, EGFR mutation accounts for approximately 10-30% of the cases, highlighting the urgent need for treatment.

Overcoming Resistance to 3rd-generation Drugs

• - Mutations in the amino acids of EGFR proteins are one of the main causes of developing resistance to NSCLC drugs.
• - Currently, the NSCLC treatment uses 1st to 3rd-generations of drugs depending on the mutations. However, the emerging issue of resistance to the third-generation drug Osimertinib (Tagrisso) raises the need for the development of new drugs. ONCOBIX is working on developing a 4th-generation lung cancer treatment such as OBX02-011 to overcome the resistance to the 3rd-generation drugs.